What is Bicara Therapeutics's stock issuance proceeds?

Bicara Therapeutics (BCAX) reported stock issuance proceeds of $161.76M in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Bicara Therapeutics BCAX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

ArriVent BioPharma, Inc.AVBP

$54.72M+740%

ImmunomeIMNM

$229K+7.5%

Arcus BiosciencesRCUS

$0-100%

Nuvation BioNUVB

$908K-16.1%

Viridian Therapeutics, Inc.VRDN

$0-100%

Summit TherapeuticsSMMT

$3.8M+88.1%

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's stock issuance proceeds?: Bicara Therapeutics (BCAX) reported stock issuance proceeds of $161.76M in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.